Opexa Therapeutics, Inc. (NASDAQ:OPXA) Files An 8-K Entry into a Material Definitive Agreement

Opexa Therapeutics, Inc. (NASDAQ:OPXA) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

Story continues below

Item 1.01 Financial Statements and Exhibits.

Reference is made to the Exhibit Index included with this Current Report on Form 8-K.

5

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Opexa Therapeutics, Inc.
Dated: July3, 2017
By:

/s/ Neil K. Warma

Neil K. Warma
President, Chief Executive Officer and Acting Chief Financial Officer

6

EXHIBIT INDEX

Exhibit No.

Description

2.1* Agreement and Plan of Merger and Reorganization, dated as of June30, 2017, by and among Opexa Therapeutics, Inc., Opexa Merger Sub, Inc. and Acer Therapeutics Inc.
2.2 Form of Support Agreement, by and between Acer Therapeutics Inc. and directors and officers of Opexa Therapeutics, Inc.
2.3 Form of Support Agreement, by and between Opexa Therapeutics, Inc. and certain directors, officers and shareholders of Acer Therapeutics Inc.
99.1 Press release, dated July 3, 2017.
* The schedules and exhibits to the Merger Agreement have been omitted
Opexa Therapeutics, Inc. Exhibit
EX-2.1 2 d362710dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION Among OPEXA THERAPEUTICS,…
To view the full exhibit click here

About Opexa Therapeutics, Inc. (NASDAQ:OPXA)

Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology. The Company’s product candidates include Tcelna and OPX-212. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient’s immune response profile to myelin. Tcelna is designed to reduce the number and/or functional activity of specific subsets of myelin-reactive T-cells (MRTCs) known to attack myelin. Tcelna is manufactured using its method for the production of an autologous T-cell product. In addition to the ongoing clinical development of Tcelna, the Company is developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.

An ad to help with our costs
/* */ // AST – IMS - [MarketExclusive_ROS]